FAHD2A

Across TCGA pan-cancer cohorts, FAHD2A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAHD2A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FAHD2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAHD2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, LIHC, and BRCA are the cancer types where FAHD2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.074	0.657	<.001	42	view →
LIHC	DFS	Median	All	0.077	0.527	.002	15	view →
BRCA	DFS	Median	All	0.592	0.903	<.001	10	view →
UCEC	DFS	Median	All	1.000	0.829	.020	10	view →
COAD	DFS	Median	All	0.225	0.690	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAHD2A–BLCA (OS)

Open the BLCA breakdown →